Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and ADME Study of Ceralasertib in Advanced Solid Tumours
NCT06754761Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- Sep 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ceralasertib in solid tumor, sponsored by AstraZeneca. Primary endpoints: Absolute Bioavailability of Ceralasertib at 5 weeks, Pharmacokinetics of Ceralasertib and [14C]-Ceralasertib at 10 weeks and 1 more. Started Sep 2025; status: terminated.
02
Drugs
ceralasertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06754761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06754761.